AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02151708
Drug: motilitone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
Trial: NCT02479854
Drug: Asmakast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 chewable tablet contains 5 mg montelukast
Trial: NCT00548860
Drug: Standard Medical Care (SMC)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04262336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable sterile viscous solution of sodium hyaluronate in sodium chloride
Trial: NCT02796807
Drug: 68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01125215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical cream base of nanoparticle apply to area with neuropathic pain twice daily for 12 weeks
Trial: NCT01310322
Drug: AZD5423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for injection, administered as intravenous infusion Corr to total dose of 250µg AZD5423
Trial: NCT01310322
Drug: AZD5423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
Trial: NCT01310322
Drug: AZD5423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
Trial: NCT01310322
Drug: AZD5423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
Trial: NCT00620594
Drug: BEZ235
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01263574
Drug: 70% ethanol
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL SPRAY [Anatizer S 70% Ethanol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of the lock solution will occur between cycles of parenteral nutrition. Lock solutions will be administered three days per week. The pre-measured volume of lock solution will then be injected into the catheter for 4 hours. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. Volume of lock solution administered will be determined by catheter size.
Trial: NCT00005861
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01332942
Drug: BAY85-3934
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received an oral single dose of placebo tablet matched to the molidustat dose (BAY85-3934) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
Trial: NCT01332942
Drug: BAY85-3934
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received an oral single dose of 5 mg of molidustat IR tablet on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
Trial: NCT01332942
Drug: BAY85-3934
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received an oral single dose of 10 mg of molidustat ( 2x 5mg IR tablets) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
Trial: NCT01332942
Drug: BAY85-3934
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received an oral single dose of 25 mg of molidustat (1 x 20 mg IR tablet and 1 x 5 mg IR tablet) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
Trial: NCT01332942
Drug: BAY85-3934
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received an oral single dose of 50 mg) of molidustat (2 x 20 mg IR tablets and 2 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
Trial: NCT01332942
Drug: BAY85-3934
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received an oral single dose of 75 mg of molidustat (3 x 20 mg IR tablets and 3 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
Trial: NCT03007394
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill to mimic lorcaserin 10mg capsule
Trial: NCT04382911
Drug: 18F-fluoroestradiol
RxNorm normalized name: fluoroestradiol (18F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the FES tracer during a PET/MRI scan
Trial: NCT01794104
Drug: LMP400
RxNorm normalized name: LMP400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Top1 inhibitors such as LMP400 are potent anticancer agents because stabilizing cleavage complex formation induces replication-and transcription-mediated DNA damage and delays DNA repair, leading to apoptosis. Preclinical and clinical data indicate that baseline tumor levels of Top1 correlate strongly with ability to respond to Top1 inhibitor therapy.
Trial: NCT01469468
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1: Single dose of simvastatin 20 mg Day 8: single dose of simvastatin 20 mg (with PF-05175157)
Trial: NCT01120210
Drug: JNJ-39588146 5 ng/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour infusion of JNJ-39588146 5 ng/kg/min on Day 1
Trial: NCT01120210
Drug: JNJ-39588146 15 ng/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour infusion of JNJ-39588146 15 ng/kg/min on Day 1
Trial: NCT01120210
Drug: JNJ-39588146 30 ng/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour infusion of JNJ-39588146 30 ng/kg/min on Day 1
Trial: NCT01120210
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour infusion of matching placebo on Day 1
Trial: NCT01120210
Drug: JNJ-39588146 5, 15, or 30 ng/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18-hour infusion of JNJ-39588146 or matching placebo on Day 1 immediately folllowing the 3-hour infusion at a dose equal to the maximum dose tolerated by that patient during the 3-hour infusion in Part 1 of the study.
Trial: NCT03618797
Drug: HL-PIF cap.160/2mg + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
Trial: NCT03618797
Drug: Livalo tab. 2mg + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin ca 2mg
Trial: NCT04296396
Drug: Fixed opioid prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 tablets of oxycodone 5mg
Trial: NCT02043015
Drug: Pre-exposure prophylaxis with FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For men who meet eligibility criteria, PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit. Men who accept PrEP will be required to have clinic visits, in addition to the regularly scheduled study visits, one month after starting PrEP and at least every 3 months afterward to monitor blood creatinine, AST/ALT and phosphorus levels.
Trial: NCT00974571
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet orally once daily at bedtime for 6 weeks
Trial: NCT03423732
Drug: CardioCell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the N-O CLI trial will receive a full dose of IMP three times during the trial: at baseline, after 45 days post index administration and after 3 months post index administration.~IMP will be administered into femoral artery and intramuscularly with 50:50 proportion. The intramuscularly dose will be administered into muscles above and below the knee in 50:50 proportion.
Trial: NCT03423732
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells.
Trial: NCT02927457
Drug: GSK2646264 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A cream for topical application with a concentration of 1% GSK2646264.
Trial: NCT02927457
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive matching Placebo topically.
Trial: NCT01857063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo chewable tablets, taken orally once daily at bedtime for 7 days
Trial: NCT02149433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01573624
Drug: FF/GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100/15.6
Trial: NCT01573624
Drug: FF/GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100/31.25
Trial: NCT01573624
Drug: FF/GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100/62.5
Trial: NCT01573624
Drug: FF/GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100/125
Trial: NCT01573624
Drug: FF/GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100/250
Trial: NCT00003585
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03306264
Drug: ASTX727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASTX727 oral tablet
Trial: NCT02202928
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
Trial: NCT04587622
Drug: Icenticaftor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 300 mg of icenticaftor (QBW251)
Trial: NCT00153491
Drug: artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00675116
Drug: GW823296
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04021264
Drug: Dextrose 5
RxNorm normalized name: Dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection
Trial: NCT01565291
Drug: florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection, 370MBq (10mCi), single dose
Trial: NCT01289808
Drug: Glucose 25%
RxNorm normalized name: glucose 25% oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml of glucose 25% once
Trial: NCT01289808
Drug: Glucose 25%
RxNorm normalized name: glucose 25% oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml glucose once per os
Trial: NCT00960635
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pill without agent
Trial: NCT02294877
Drug: Vimizim® (elosulfase alfa)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human N acetylgalactosamine 6 sulfatase (rhGALNS)
Trial: NCT02850003
Drug: IDP-120 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel
Trial: NCT00864474
Drug: CELSENTRI® Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CELSENTRI ® Tablets 150mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage is 300 mg twice daily. Maraviroc must be used in combination with other anti-HIV drugs. The dosage may be adjusted according to co-administered medical products. Maraviroc can be taken with or without food.
Trial: NCT00567775
Drug: inhaled human insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01707004
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00727194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV weekly for 4 doses then every two weeks for 7 doses
Trial: NCT01763164
Drug: MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.
Trial: NCT01234129
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years
Trial: NCT03152318
Drug: rQNestin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rQNestin is an oncolytic viral vector. It is administered via intratumoral injection during biopsy surgery.
Trial: NCT03152318
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is an immunomodulating agent. It is administered intravenously in a single dose 2 days (+/- 6 hrs) before surgery.
Trial: NCT02837432
Drug: Hydrocortisone acetate
RxNorm normalized name: Hydrocortisone Acetate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02837432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05518279
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the control arm will receive 3 placebo pills while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the placebo pills and are medically optimized for surgery, they will be taken to the operating room for fracture fixation.
Trial: NCT00779454
Drug: Gemcitabine, Oxaliplatin, Capecitabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabin: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7
Trial: NCT00779454
Drug: Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7 Panitumumab: 6 mg/kg day 1
Trial: NCT00184899
Drug: Intravenous infusion of Intralipid/heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00184899
Drug: Intravenous infusion of Glycerol/heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00071812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
Trial: NCT01896895
Drug: IncobulinumtoxinA (Xeomin), 25 Units
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 25 Units per eye.
Trial: NCT01896895
Drug: IncobotulinumtoxinA (Xeomin), 12.5 Units
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 12.5 Units per eye.
Trial: NCT01896895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Trial: NCT01896895
Drug: IncobotulinumtoxinA (Xeomin), 35 Units
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Open-Label Extension: up to 35 Units per eye.
Trial: NCT01396369
Drug: Birth control plus Brevail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H\&P as well as repeat ultrasound and blood tests.
Trial: NCT01484964
Drug: ASP015K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03709927
Drug: ZTI-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6g IV fosfomycin
Trial: NCT03692416
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infants and children with vasculitis attending AssiutU, aged \> 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Ibuprofen for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique.
Trial: NCT00667342
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV.
Trial: NCT00667342
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV.
Trial: NCT01911507
Drug: INC280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03672435
Drug: Topical Solution
RxNorm normalized name: Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: proparacaine 0.5% eye drop
Trial: NCT00394030
Drug: GSK716155 subcutaneous injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK716155 will be available as lyophilize uniform cake in 10 milliliter (mL) clear glass vials with 20 millimeter (mm) closure. Subjects will administer dose of either 16mg or 64mg of GSK716155 via subcutaneous injection(s). For dose of 16 mg 1 injection of 0.62 mL will be administered and for dose of 64 mg 3 injections of 0.82 mL each will be administered.
Trial: NCT03734848
Drug: Bilateral Ultrasound Guided Pectoralis Nerve Block.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using a 20-gauge 5 cm needle. Injection bupivacaine 0.25% used as a local anesthetic. The block was performed in a supine position with the arm slightly abducted. The ultrasound probe was placed at the midclavicular level infero-laterally to locate the axillary artery and vein and then moved laterally toward the axilla until pectoralis major, pectoralis minor, and serratus anterior muscles were identified at the level of the fourth rib. The needle was inserted in-plane with respect to the ultrasound probe. A volume of 20 ml of local anesthetic solution was deposited in the fascial plane between pectoralis minor and serratus anterior muscle, followed by withdrawal of the needle to the fascial plane between the pectoralis major and pectoralis minor muscle, where a volume of 10 ml was deposited. The block was performed similarly on the opposite side. Care was taken not to cross the toxic dose of bupivacaine (3 mg/kg).
Trial: NCT02178033
Drug: Split dose low-volume PEG solution
RxNorm normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®, Norgine, Harefield, United Kingdom); in the control arm the whole colonoscopy preparation is administered the day before colonoscopy; in the  active comparator  arm one liter of the bowel preparation is administered on the evening before the colonoscopy and the remaining liter on the day of the procedure.
Trial: NCT01332617
Drug: Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Simvastatin 80 mg PO daily starting day -2 through day 10.~2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly~3. Bortezomib 1.3 mg/m2/day IV bolus on days 3,6 and 10.~4. Bendamustine 100 mg/m2/day IV over 30 minute infusion on days 3 and 10.~5. Methylprednisolone 1g/m2 IV over 30 minutes on days 1 and 8.
Trial: NCT00460941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sc weekly
Trial: NCT00003491
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT01746784
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous solution of 0.9% (weight/volume) NaCl administered by infusion pump over 1-8 minutes depending on dose of active drug used in same cohort
Trial: NCT01233375
Drug: CO-1.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1250 mg/m2/day administered on Days 1, 8, and 15 in 4-week treatment cycles.~Patients who have SD or better at the Week 8 assessment and who adequately tolerated the first 2 cycles of treatment may continue CO-1.01 at the same or an increased dose (1400 mg/m2) for Cycle 3 and subsequent cycles.